Lunit, a leading provider of AI for cancer diagnostics and precision oncology, announced a strategic collaboration with Discovery Life Sciences (Discovery), a global leader in biospecimens and specialty laboratory services, to expand the adoption of the Lunit SCOPE suite, the company's AI-powered pathology platform, across biopharmaceutical research.
Through the collaboration, Discovery and Lunit will work together with biopharma clients to apply the Lunit SCOPE suite within Discovery's biomarker and tissue analysis workflows, tailoring AI-powered pathology to each program's design. By pairing Discovery's global biospecimen network and specialty laboratory expertise with Lunit's AI-powered image analysis on client programs, the companies aim to provide pharmaceutical and biotechnology companies with standardized, quantitative tissue insights that support clinical research, translational studies, and drug development. The collaboration is expected to broaden global access to Lunit's AI-powered pathology platform for biopharmaceutical researchers and organizations.
The companies also plan to expand AI-enabled tissue analysis services that help researchers generate deeper biological insights, improve the reproducibility of tissue-based analysis, and accelerate evidence generation throughout the drug development process.